NanoViricides to Launch Phase II MPox Trial in Democratic Republic of Congo

NanoViricides, Inc. announced that a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo, with site preparation and staff training scheduled for early April 2026. The study, already approved by the DRC regulatory agency, will evaluate the safety and effectiveness of NV-387 against Clade I MPox, as the company advances regulatory development and seeks Orphan Drug Designation from the U.S. FDA. This trial represents a significant step in addressing a viral disease that has caused outbreaks in Central Africa, where Clade I MPox has higher mortality rates compared to other strains. The company's broader development strategy includes NV-387 as a potential treatment for multiple respiratory viral infections, including RSV, COVID, Long COVID, and Influenza, positioning it as a versatile antiviral platform.

The company's lead drug candidate, NV-387, is a broad-spectrum antiviral drug that the company plans to develop for various infections. According to the company's website at https://www.nanoviricides.com, NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. The company's novel nanoviricide class of drug candidates is based on intellectual property from TheraCour Pharma, Inc., with a Memorandum of Understanding for developing drugs for antiviral infections. This trial in the DRC is critical because it targets a region heavily affected by MPox, providing real-world data on the drug's efficacy in a high-need population. The pursuit of Orphan Drug Designation could offer regulatory and financial incentives, accelerating the drug's development and potential approval.

NanoViricides' platform technology and programs are based on the TheraCour nanomedicine technology, which the company licenses for specific viral diseases. The company holds exclusive licenses for diseases such as HIV/AIDS, Hepatitis B and C, Rabies, and Influenza, among others. As stated in the press release, the path to drug development is lengthy and requires substantial capital, with no assurance of success in clinical trials. However, this Phase II trial marks progress in the company's pipeline, which also includes candidates for Shingles, Herpes, and other viral diseases. The trial's initiation in the DRC underscores the global health implications, as effective treatments for MPox could mitigate outbreaks and reduce mortality in endemic regions.

The company's business model involves licensing technology from TheraCour Pharma Inc. for specific application verticals of viruses. In addition to MPox, NanoViricides is developing drugs against viral diseases like Ebola, Dengue fever, and seasonal Influenza. The Phase II trial for NV-387 in the DRC is part of this broader effort, with the company currently focused on advancing NV-387 into Phase II human clinical trials. This move could have significant implications for public health, especially in areas with limited access to antiviral therapies. For more information on the company's updates, news is available at https://ibn.fm/NNVC, though the trial's success will depend on rigorous clinical evaluation and regulatory milestones.